News
News
Academy
Multimedia
Editorial PodcastsEditorial VideosPeer ExchangeProfiles in Medicine
Conferences
Conference CoverageConference Listing
More
Publications
Pharmaceutical Executive
Partner Perspectives
Resources
Content Engagement HubsE-BooksEventsSponsored PodcastsSponsored VideosWebcastsWhitepapers

Subscribe

  • News
  • Academy
  • Multimedia
  • Conferences
  • Publications
  • Partner Perspectives
  • Resources
  • Subscribe
  • Corporate Communications
    • Press Releases
    • Executive Roundtable
    • Executive Profiles
    • Leadership
  • Direct-to-Consumer
    • Patient Education
    • Healthcare Access
    • Telehealth
  • Emerging Biopharma
    • Partnerships
    • Funding
  • IR Licensing and Partnerships
    • Finance
    • Industry Trends
  • Market Access
    • Patient Access
    • Pricing
    • Strategy
  • Medical Affairs
    • Patient Advocacy
    • Clinical Data
    • Pharmacovigilance
  • Operations
    • Sustainability
    • Technology
    • R&D/Clinical Trials
    • Supply Chain
  • Patient Engagement
    • DE&I
  • Regulatory
    • FDA
    • Legal
    • Global
  • Sales & Marketing
    • Sales Effectiveness
    • Campaigns
    • DTC Marketing
    • Medical Education
Spotlight -
Latest Executive Roundtables|
Asembia 2025 |
Sales Effectiveness
Advertisement

Chris Conner

Advertisement

Chris Conner, Director of Marketing, Association Commercial Professionals – Life Sciences and Host of the Life Science Marketing Radio Podcast

Articles by Chris Conner

Customer Experience: A Buzz Term or a Source of Real Commercial Value?

ByChris Conner
June 1st 2017

Exploring the importance of a customer experience strategy (CXM) through a case study of a life science tools company.

Advertisement

Latest Updated Articles

  • Customer Experience: A Buzz Term or a Source of Real Commercial Value?
    Customer Experience: A Buzz Term or a Source of Real Commercial Value?

    Published: June 1st 2017 | Updated:



Advertisement
Advertisement

Trending on PharmExec

1

Roche Announces Positive Topline Results from Phase II Study for Dual GLP-1/GIP Receptor Agonist

2

Boehringer Ingelheim Enters $1.26 Billion Collaboration and License Agreement with Simcere Pharmaceuticals to Develop Pre-Clinical Bispecific Antibody

3

What Trends Did You See at This Year's JP Morgan Healthcare Conference?

4

Mirum Pharmaceuticals Completes $268.6 Million Acquisition of Bluejay Therapeutics to Strengthen Rare Disease Pipeline

5

Pharmaceutical Executive Daily: Roche Reports Positive Phase II Study Results for Dual GLP-1/GIP Receptor Agonist

  • About
  • Advertise
  • Contact Us
  • Editorial Board
  • Editorial Submission Guidelines
  • Do Not Sell My Personal Information
  • Privacy Policy
  • Terms and Conditions
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

Brand Logo

© 2025 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us